Sandip M Kanse

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7555601/publications.pdf

Version: 2024-02-01

91	3,729	117625	133252
papers	citations	34 h-index	59 g-index

93	93	93	3599
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Factor VII activating protease (FSAP) is not essential in the pathophysiology of angioedema in patients with C1 inhibitor deficiency. Molecular Immunology, 2022, 142, 95-104.	2.2	4
2	Proteolytic activation of the epithelial sodium channel (ENaC) by factor VII activating protease (FSAP) and its relevance for sodium retention in nephrotic mice. Pflugers Archiv European Journal of Physiology, 2022, 474, 217-229.	2.8	17
3	Persistent hypercoagulability in dogs envenomated by the European adder (Vipera berus berus). PLoS ONE, 2022, 17, e0263238.	2.5	1
4	Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia. Scientific Reports, 2021, 11, 5127.	3.3	11
5	uPAâ€PAIâ€1 heteromerization promotes breast cancer progression by attracting tumorigenic neutrophils. EMBO Molecular Medicine, 2021, 13, e13110.	6.9	5
6	Protease activated receptors (PAR)â€1 and â€2 mediate cellular effects of factor VII activating protease (FSAP). FASEB Journal, 2020, 34, 1079-1090.	0.5	15
7	Rebuttal to editorial: Sodium retention by uPA in nephrotic syndrome?. Acta Physiologica, 2020, 228, e13427.	3.8	3
8	Vitronectin stabilizes intravascular adhesion of neutrophils by coordinating beta2 integrin clustering. Haematologica, 2020, 106, haematol.2019.226241.	3.5	9
9	Factor VII Activating Protease Expression in Human Platelets and Accumulation in Symptomatic Carotid Plaque. Journal of the American Heart Association, 2020, 9, e016445.	3.7	5
10	Design and Characterization of a New pVII Combinatorial Phage Display Peptide Library for Protease Substrate Mining Using Factor VII Activating Protease (FSAP) as Model. ChemBioChem, 2020, 21, 1875-1884.	2.6	4
11	Cellular effects of factor VII activating protease (FSAP). Thrombosis Research, 2020, 188, 74-78.	1.7	5
12	Elevated Complement C3 and C4 Levels are Associated with Postnatal Pregnancy-Related Venous Thrombosis. Thrombosis and Haemostasis, 2019, 119, 1481-1488.	3.4	4
13	VEGF-A-Cleavage by FSAP and Inhibition of Neo-Vascularization. Cells, 2019, 8, 1396.	4.1	7
14	Fluorescent activity-based probe for the selective detection of Factor VII activating protease (FSAP) in human plasma. Thrombosis Research, 2019, 182, 124-132.	1.7	10
15	Urokinaseâ€type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)â€mediated sodium retention in experimental nephrotic syndrome. Acta Physiologica, 2019, 227, e13286.	3.8	36
16	Characterization of the enzymatic activity of the serine protease domain of Factor VII activating protease (FSAP). Scientific Reports, 2019, 9, 18990.	3.3	13
17	Plasminogen Activator Inhibitor-1 Promotes Neutrophil Infiltration and Tissue Injury on Ischemiaâ€“Reperfusion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 829-842.	2.4	51
18	Interaction of factor VII activating protease (FSAP) with neutrophil extracellular traps (NETs). Thrombosis Research, 2018, 161, 36-42.	1.7	25

#	Article	IF	Citations
19	Post-transcriptional, post-translational and pharmacological regulation of tissue factor pathway inhibitor. Blood Coagulation and Fibrinolysis, 2018, 29, 668-682.	1.0	6
20	Genetics of the thrombomodulin-endothelial cell protein C receptor system and the risk of early-onset ischemic stroke. PLoS ONE, 2018, 13, e0206554.	2.5	8
21	Altered structure and function of fibrinogen after cleavage by Factor VII Activating Protease (FSAP). Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3397-3406.	3.8	11
22	Tissue Factor Pathway Inhibitor Enhances Transendothelial Migration of Chronic Lymphocytic Leukemia Cells through Binding to Glypican-3. Blood, 2018, 132, 2452-2452.	1.4	0
23	The pseudophosphatase <scp>STYX</scp> targets the Fâ€box of <scp>FBXW</scp>7 and inhibits <scp>SCF</scp>^{FBXW7} function. EMBO Journal, 2017, 36, 260-273.	7.8	26
24	Factor VII activating protease (FSAP) regulates the expression of inflammatory genes in vascular smooth muscle and endothelial cells. Atherosclerosis, 2017, 265, 133-139.	0.8	17
25	Tissue factor pathway inhibitor attenuates ER stress-induced inflammation in human M2-polarized macrophages. Biochemical and Biophysical Research Communications, 2017, 491, 442-448.	2.1	19
26	A Positively Charged Surface Triggers Coagulation Activation Through Factor VII Activating Protease (FSAP). ACS Applied Materials & Interfaces, 2017, 9, 40107-40116.	8.0	50
27	Analysis of the substrate specificity of Factor VII activating protease (FSAP) and design of specific and sensitive peptide substrates. Thrombosis and Haemostasis, 2017, 117, 1750-1760.	3.4	16
28	A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. Thrombosis Research, 2017, 157, 111-116.	1.7	21
29	Factor VII activating protease (FSAP) influences vascular remodeling in the mouse hind limb ischemia model. American Journal of Translational Research (discontinued), 2017, 9, 3084-3095.	0.0	7
30	Factor seven activating protease (FSAP) predicts response to intravenous thrombolysis in acute ischemic stroke. International Journal of Stroke, 2016, 11, 646-655.	5.9	13
31	Transforming Growth Factor-Î² (TGF-Î²) Inhibits the Expression of Factor VII-activating Protease (FSAP) in Hepatocytes. Journal of Biological Chemistry, 2016, 291, 21020-21028.	3.4	10
32	Perivascular Mast Cells Govern Shear Stress-Induced Arteriogenesis by Orchestrating Leukocyte Function. Cell Reports, 2016, 16, 2197-2207.	6.4	55
33	Factor VIIâ€activating protease deficiency promotes neointima formation by enhancing leukocyte accumulation. Journal of Thrombosis and Haemostasis, 2016, 14, 2058-2067.	3.8	14
34	Genome-Wide Association Analysis of Young-Onset Stroke Identifies a Locus on Chromosome 10q25 Near HABP2. Stroke, 2016, 47, 307-316.	2.0	54
35	Defective thrombus formation in mice lacking endogenous factor VII activating protease (FSAP). Thrombosis and Haemostasis, 2015, 113, 870-880.	3.4	32
36	Components of the Plasminogen Activation System Promote Engraftment of Porous Polyethylene Biomaterial via Common and Distinct Effects. PLoS ONE, 2015, 10, e0116883.	2.5	9

#	Article	IF	Citations
37	Deficiency of Factor <scp>VII</scp> activating protease alters the outcome of ischemic stroke in mice. European Journal of Neuroscience, 2015, 41, 965-975.	2.6	29
38	Ferric Chlorideâ€“Induced Arterial Thrombosis in Mice. Current Protocols in Mouse Biology, 2014, 4, 151-164.	1.2	5
39	Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study. Journal of Thrombosis and Thrombolysis, 2014, 37, 317-325.	2.1	3
40	Factor VII activating protease (FSAP): A novel protective factor in liver fibrosis. Proteomics - Clinical Applications, 2014, 8, 438-446.	1.6	8
41	Factor seven activating protease (FSAP) expression in human placenta and its role in trophoblast migration. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2013, 167, 34-40.	1.1	4
42	Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men. Journal of Hepatology, 2013, 58, 104-111.	3.7	32
43	Regulation of monocyte/macrophage function by factor VII activating protease (FSAP). Atherosclerosis, 2013, 230, 365-372.	0.8	15
44	Factor VII-Activating Protease Is Activated in Multiple Trauma Patients and Generates Anaphylatoxin C5a. Journal of Immunology, 2012, 188, 2858-2865.	0.8	68
45	Factor VIIâ€“Activating Protease Promotes the Proteolysis and Inhibition of Tissue Factor Pathway Inhibitor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 427-433.	2.4	43
46	The vitamin Kâ€“dependent anticoagulant factor, protein S, inhibits multiple VEGF-Aâ€“induced angiogenesis events in a Mer- and SHP2-dependent manner. Blood, 2012, 120, 5073-5083.	1.4	38
47	Circulating Factor VII Activating Protease (FSAP) Is Associated With Clinical Outcome in Acute Coronary Syndrome. Circulation Journal, 2012, 76, 2653-2661.	1.6	22
48	At the Interface of Fibrinolysis and Inflammation: The Role of Urokinase-Type Plasminogen Activator in the Leukocyte Extravasation Cascade. Trends in Cardiovascular Medicine, 2012, 22, 192-196.	4.9	28
49	Cathepsin D is released after severe tissue trauma in vivo and is capable of generating C5a in vitro. Molecular Immunology, 2012, 50, 60-65.	2.2	35
50	Nicotine Modulation of Factor VII Activating Protease (FSAP) Expression in Human Monocytes. Journal of Atherosclerosis and Thrombosis, 2012, 19, 962-969.	2.0	6
51	Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality. Stroke Research and Treatment, 2011, 2011, 1-6.	0.8	39
52	Urokinase-Type Plasminogen Activator Promotes Paracellular Transmigration of Neutrophils Via Mac-1, But Independently of Urokinase-Type Plasminogen Activator Receptor. Circulation, 2011, 124, 1848-1859.	1.6	40
53	Factor Seven Activating Protease (FSAP) levels during normal pregnancy and in women using oral contraceptives. Thrombosis Research, 2010, 126, e36-e40.	1.7	15
54	Structure â€“ function analysis of factor VII activating protease (FSAP): Sequence determinants for heparin binding and cellular functions. FEBS Letters, 2009, 583, 1994-1998.	2.8	13

#	Article	IF	Citations
55	The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology, 2009, 49, 775-780.	7.3	39
56	High negative chargeâ€toâ€size ratio in polyphosphates and heparin regulates factorâ€ƒVIIâ€activating protease. FEBS Journal, 2009, 276, 4828-4839.	4.7	36
57	Altered factor VII activating protease expression in murine hepatic fibrosis and its influence on hepatic stellate cells. Liver International, 2009, 29, 686-691.	3.9	11
58	A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells. Blood, 2009, 113, 714-722.	1.4	63
59	Factor Seven Activating Protease (FSAP) expression in human monocytes and accumulation in unstable coronary atherosclerotic plaques. Atherosclerosis, 2008, 196, 164-171.	0.8	40
60	Factor VII-activating protease (FSAP): Vascular functions and role in atherosclerosis. Thrombosis and Haemostasis, 2008, 99, 286-289.	3.4	68
61	Plasminogen Activator Inhibitor-1 Is an Inhibitor of Factor VII-activating Protease in Patients with Acute Respiratory Distress Syndrome. Journal of Biological Chemistry, 2007, 282, 21671-21682.	3.4	42
62	Inhibition of PDGF-BB by Factor VII-activating protease (FSAP) is neutralized by protease nexin-1, and the FSAPâ€“inhibitor complexes are internalized via LRP. Biochemical Journal, 2007, 404, 191-196.	3.7	33
63	Nucleic acids potentiate Factor VII-activating protease (FSAP)-mediated cleavage of platelet-derived growth factor-BB and inhibition of vascular smooth muscle cell proliferation. Biochemical Journal, 2007, 404, 45-50.	3.7	19
64	Urokinase Receptor (CD87) Clustering in Detergent-Insoluble Adhesion Patches Leads to Cell Adhesion Independently of Integrins. Cell Communication and Adhesion, 2007, 14, 137-155.	1.0	5
65	Rapid genotyping of the G534E polymorphism (Marburg I) of the gene encoding the factor VII-activating protease (FSAP) by LightCycler PCR. Clinical Biochemistry, 2007, 40, 1063-1064.	1.9	11
66	A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding. Biochemical Journal, 2006, 394, 687-692.	3.7	34
67	The G534E polymorphism of the gene encoding the factor VIIâ€“activating protease is associated with cardiovascular risk due to increased neointima formation. Journal of Experimental Medicine, 2006, 203, 2801-2807.	8.5	71
68	Characterisation and partial purification of Schistosoma mansoni egg-derived pro-angiogenic factor. Molecular and Biochemical Parasitology, 2005, 144, 76-85.	1.1	18
69	Reciprocal regulation of urokinase receptor (CD87)-mediated cell adhesion by plasminogen activator inhibitor-1 and protease nexin-1. Journal of Cell Science, 2004, 117, 477-485.	2.0	27
70	Factor VII activating protease (FSAP) inhibits growth factorâ€mediated cell proliferation and migration of vascular smooth muscle cells.. FASEB Journal, 2004, 18, 728-730.	0.5	53
71	Promotion of Leukocyte Adhesion by a Novel Interaction Between Vitronectin and the Î²2Integrin Mac-1 (Î±MÎ²2, CD11b/CD18). Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2251-2256.	2.4	46
72	Variability in the expression of urokinase receptor(CD87) mutants on cells: relevance to cell adhesion. Cell Biochemistry and Function, 2004, 22, 257-264.	2.9	2

#	Article	IF	Citations
73	New Aspects of Integrin-mediated Leukocyte Adhesion in Inflammation: Regulation by Haemostatic Factors and Bacterial Products. Current Molecular Medicine, 2003, 3, 387-392.	1.3	19
74	Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood, 2002, 100, 3611-3617.	1.4	63
75	Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nature Medicine, 2002, 8, 687-693.	30.7	230
76	Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB Journal, 2001, 15, 2365-2376.	0.5	59
77	Urokinase receptor: a molecular organizer in cellular communication. Current Opinion in Cell Biology, 2000, 12, 621-628.	5.4	200
78	Urokinase Receptor (CD87) Regulates Leukocyte Recruitment via Î²2 Integrins In Vivo. Journal of Experimental Medicine, 1998, 188, 1029-1037.	8.5	270
79	Plasminogen Activator Inhibitor-1 Represses Integrin- and Vitronectin-Mediated Cell Migration Independently of Its Function as an Inhibitor of Plasminogen Activation. Experimental Cell Research, 1997, 232, 420-429.	2.6	221
80	Isolation and characterization of the circulating form of human endostatin. FEBS Letters, 1997, 420, 129-133.	2.8	102
81	The Urokinase Receptor Is a Major Vitronectin-Binding Protein on Endothelial Cells. Experimental Cell Research, 1996, 224, 344-353.	2.6	241
82	Involvement of Pertussis toxin-sensitive and -insensitive G proteins in Î±-thrombin signalling on cultured human vascular smooth muscle cells. Cellular Signalling, 1996, 8, 59-66.	3.6	27
83	Cytokine stimulated endothelin release from endothelial cells. Life Sciences, 1991, 48, 1379-1384.	4.3	77
84	Glucocorticoids induce endothelin release from vascular smooth muscle cells but not endothelial cells. European Journal of Pharmacology, 1991, 199, 99-101.	3.5	60
85	Presence of immunoreactive endothelin in human saliva and rat parotid gland. Peptides, 1991, 12, 883-885.	2.4	15
86	Peptide Contents of Neuropeptide Y, Vasoactive Intestinal Polypeptide, andÎ²-Calcitonin Gene-Related Peptide and Their Messenger Ribonucleic Acids after Dexamethasone Treatment in the Isolated Rat Islets of Langerhans. Endocrinology, 1991, 129, 3372-3380.	2.8	58
87	Binding sites of a novel neuropeptide pituitary-adenylate-cyclase-activating polypeptide in the rat brain and lung. FEBS Journal, 1990, 193, 725-729.	0.2	130
88	Release of Substance P from Rat Hypothalamus and Pituitary by Endothelin. Endocrinology, 1990, 126, 2288-2295.	2.8	60
89	Endothelin binding sites in porcine-aortic and rat lung membranes. FEBS Journal, 1989, 182, 175-179.	0.2	48
90	Characterization of glucagon-like peptide-1-(7â€“36)amide in the hypothalamus. Brain Research, 1989, 502, 325-331.	2.2	98

#	Article	IF	Citations
91	Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung. FEBS Letters, 1988, 241, 209-212.	2.8	96